Zynerba starts Ph I study of cannabinoid pain patch

By Gareth Macdonald contact

- Last updated on GMT


Related tags: U.s. securities and exchange commission

Zynerba Pharmaceuticals Inc has begun a Phase I trial of cannabinoid patch it is developing for fibromyalgia and peripheral neuropathic pain.

The study – details of which were provided in a US Securities and Exchange Commission (SEC) filing​ - will examine the safety and tolerability of ZYN001, which is a pro-drug of tetrahydrocannabinol (THC) that is delivered using a transdermal patch.

ZYN001 is the second Zynerba transdermal, cannabinoid based product in clinical development after ZYN002, a synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for application to the skin.

The drug, which is being developed to treat epilepsy, is being examined in a Phase I study in Australia, in collaboration with contract research organisation (CRO) Novotech.

Related news

Show more

Related products

show more

A Better Approach, for Better Pain Trials

A Better Approach, for Better Pain Trials

Signant Health | 27-Sep-2021 | Technical / White Paper

Pain studies face unique challenges. For one, pain severity can only be truly assessed by the patients themselves. The controlled substances that are often...

Related suppliers

Follow us


View more